Table 1 Demographic data for the 151 patients
Patients | 82.8% women |
|---|---|
Age (years) | 51.4 ± 13.2 |
Anti-CCP | 80.1% positive |
Rheumatoid factor | 75.2% positive |
Disease duration (years) | 9.9 ± 7.9 |
Number of swollen joints | 6.49 ± 5.5 |
Number of tender joints | 5.98 ± 6.4 |
bDMARDs initiated in the study cohort | Infliximab (n = 19), etanercept (n = 59), adalimumab (n = 8), certolizumab (n = 12), golimumab (n = 8), rituximab (n = 30), tocilizumab (n = 8), and abatacept (n = 5); 8% of the patients were biologic naive |
Prednisolone treated | 50.7% |
Prednisolone dose | 7.8 ± 4.68 mg |
DAS28-CRP score | 4.14 ± 1.32) |
Total number of joints examined, n | 5225 |
Joints with SH and no Doppler at baseline, n (%) | 1191 (23%) |
Joints with SH and Doppler at baseline, n (%) | 1151 (22%) |